Stryker (NYSE:SYK) Issues Quarterly Earnings Results

Stryker (NYSE:SYK) announced its quarterly earnings data on Thursday. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38), FiscalAI reports. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.74% and a net margin of 13.20%.The business’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.84 EPS. Stryker updated its FY 2026 guidance to 14.900-15.100 EPS.

Here are the key takeaways from Stryker’s conference call:

• The company experienced a late‑Q1 cyber incident that caused a global operational disruption, delayed shipments and revenue recognition, and reduced manufacturing absorption; Stryker says systems were restored and manufacturing was fully operational by the week of April 1, with results expected to normalize over the year.
• Stryker reiterated full‑year guidance despite the disruption, forecasting organic net sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, expecting most lost Q1 sales to be recovered throughout the rest of 2026.
• Q1 headline metrics were muted—organic sales growth of 2.4% (U.S. 1.9%, international 3.9%), adjusted EPS of $2.60 (down 8.5% vs. 2025), adjusted gross margin 63.6% (‑190 bps) and adjusted operating margin 21.1% (‑180 bps), with tariffs, higher interest expense and the cyber event cited as drivers.
• M&A remains active—Stryker announced the agreement to acquire Amplitude Vascular Systems (expected to close in Q2) to expand peripheral vascular and broader cardiovascular offerings and said it has capacity to pursue additional acquisitions (gross debt/EBITDA ~2.1x).
• Organizational and product momentum in orthopedics—Stryker launched the consolidated Ortho Tech segment (Mako + Enabling Tech + instruments), reported a record Q1 for Mako installations, plans a Mako Shoulder full launch on Mako 4 midyear, and cited strong early feedback for new robotic and instrument products.

Stryker Price Performance

NYSE:SYK traded down $19.70 during mid-day trading on Friday, hitting $295.43. 4,518,113 shares of the stock traded hands, compared to its average volume of 1,836,681. The business’s 50-day moving average price is $345.67 and its 200 day moving average price is $356.95. The company has a market cap of $113.15 billion, a PE ratio of 35.17, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92. Stryker has a 12-month low of $294.55 and a 12-month high of $404.87. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s payout ratio is currently 41.90%.

Analysts Set New Price Targets

Several brokerages have commented on SYK. Barclays reaffirmed an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research report on Monday, February 2nd. Truist Financial reduced their target price on shares of Stryker from $395.00 to $380.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research note on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $401.43.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Several hedge funds have recently bought and sold shares of SYK. Wellington Management Group LLP grew its stake in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC grew its stake in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Credit Agricole S A bought a new stake in Stryker during the third quarter valued at approximately $194,045,000. Dimensional Fund Advisors LP lifted its position in Stryker by 35.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,260,651 shares of the medical technology company’s stock valued at $443,113,000 after purchasing an additional 327,490 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Stryker by 293.6% during the fourth quarter. Renaissance Technologies LLC now owns 406,160 shares of the medical technology company’s stock valued at $142,753,000 after purchasing an additional 302,960 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.